Clinical trials: Mental
ADHD, Comorbid Alcohol Abuse
Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse
Atomoxetine Treatment of Adults with ADHD and Comorbid Alcohol Abuse
- Trial name
- NCT00190957
- Testing
- Atomoxetine
- Where
- 15 sites in United States, Canada
- Volunteers
- 140 people
- Sponsor
- Eli Lilly and Company
Severe Postpartum Depression
A Study of BRII-296 in Adults With Severe Postpartum Depression (PPD)
The primary purpose of this study is to evaluate the safety and tolerability of BRII-296 administered by 2 intramuscular injections, administered with Depo Medrol as assessed by the incidence of adverse events, changes from…
- Trial name
- NCT06057012
- Testing
- BRII-296, Depo Medrol
- Where
- 11 sites in United States
- Volunteers
- 11 people
- Sponsor
- Brii Biosciences Limited
Alzheimer's Disease
Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease
The objective of this study is to evaluate the effect of memantine versus placebo on functional communication in patients with Alzheimer's Disease
- Trial name
- NCT00469456
- Testing
- Memantine
- Where
- 25 sites in Australia, New Zealand and 1 more
- Volunteers
- 265 people
- Sponsor
- Forest Laboratories
Alcohol Use Disorder
PT150 Drug for Use in Alcohol Use Disorder
The goal of this study is to learn if PT150 can reduce the behavioral and physical effects of stress, alcohol, and alcohol use in people with alcohol use disorder.
- Trial name
- NCT06712602
- Testing
- alcohol, Stress-Induction, PT150
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Pop Test Oncology LLC
Autistic Disorder
A Longitudinal Study on the Safety and Efficacy for Subjects With ASD Who Received MeRT
The purpose of this study is to continue to evaluate the long-term effectiveness of Magnetic EEG/ECG-Guided Resonance Therapy (MeRT) in children with Autism Spectrum Disorder (ASD).
- Trial name
- NCT02746445
- Testing
- No intervention
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Wave Neuroscience
Schizophrenia
A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings
The purpose of this study is to assess the long-term symptomatic response (Visit 2 [Week 1] to Visit 14/Week 66 [End of Study {EOS}]) measured by change in the Clinical Global Impressions -Severity for Schizophrenia (CGI-SS) in…
- Trial name
- CASPAR (NCT04940039)
- Testing
- Risperidone 3 mg, Paliperidone Palmitate 50 mg eq., Paliperidone Palmitate 75 mg eq.
- Where
- 5 sites in Rwanda
- Volunteers
- 93 people
- Sponsor
- Janssen-Cilag International NV
Schizophrenia
A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia
A Clinical Study to learn if SEP-363856 has physical dependence in adults with schizophrenia. This study will be held in approximately 6 study sites in the United States.
- Trial name
- NCT05848700
- Testing
- SEP-363856
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorder, Manic
Study of Lumateperone in the Treatment of Patients With Bipolar Mania
This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with…
- Trial name
- NCT06462612
- Testing
- Lumateperone
- Where
- 35 sites in United States, Bulgaria and 2 more
- Volunteers
- 351 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Schizophrenia
Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia
The purpose of this study is to determine whether cognitive impairment associated with schizophrenia is attenuated by add-on roflumilast administration to second generation antipsychotics (SGA) in participants with stable…
- Trial name
- NCT02079844
- Testing
- Roflumilast, Second generation antipsychotic
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Takeda
Alcohol Use Disorder
An Open-Label, Single Dose Study in Patients With Alcohol Use Disorder
An open-label, Phase 2a study to evaluate the safety, tolerability, and pharmacodynamic effects of a single intranasal dose of BPL-003 combined with relapse prevention psychological support, to explore the potential effects on…
- Trial name
- NCT05674929
- Testing
- BPL-003
- Where
- 2 sites in United Kingdom
- Volunteers
- 13 people
- Sponsor
- Beckley Psytech Limited
Major Depressive Disorder
Major Depressive Disorder With Mixed Features - Extension
Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features…
- Trial name
- RESOLVE3 (NCT01423253)
- Testing
- Lurasidone
- Where
- 17 sites in United States
- Volunteers
- 48 people
- Sponsor
- Sumitomo Pharma America, Inc.
Opioid Dependence
Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence
Buprenorphine (BPN) is an approved treatment for opioid dependence; however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low.
- Trial name
- PRO-807 (NCT00630201)
- Testing
- Probuphine (buprenorphine implant)
- Where
- 15 sites in United States
- Volunteers
- 62 people
- Sponsor
- Titan Pharmaceuticals
Prader-Willi Syndrome
A Study of Pitolisant in Patients With Prader-Willi Syndrome
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, global clinical study to assess the efficacy and safety of pitolisant in patients living with Prader-Willi syndrome.
- Trial name
- NCT06366464
- Testing
- Pitolisant tablet
- Where
- 57 sites in United States, Australia and 11 more
- Volunteers
- 134 people
- Sponsor
- Harmony Biosciences Management, Inc.
Bipolar Disorder
Study Measuring Differences in Cognition Due to Sedative Effects of Risperidone and Quetiapine in Stable Bipolar I Outpatients
The purpose of this study is to determine whether the sedating (causing sleepiness) effects of risperidone or quetiapine alter cognitive (person's ability to think, perceive, recognize, remember, judge, and reason) functioning in…
- Trial name
- NCT00097032
- Testing
- risperidone; quetiapine
- Volunteers
- 30 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Narcolepsy Without Cataplexy, Narcolepsy With Cataplexy
Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy
This EAP will be open to provide access to treatment with pitolisant while a U.S. New Drug Application (NDA) is being prepared and submitted for review for marketing approval.
- Trial name
- NCT03433131
- Testing
- Pitolisant
- Where
- 71 sites in United States
- Sponsor
- Harmony Biosciences Management, Inc.
Alzheimer's Disease
Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)
The primary objective is to evaluate the efficacy of T-817MA as measured by ADAS-cog and ADCS-CGIC. The secondary objectives are: To evaluate the safety and tolerability of T-817MA measured by clinical safety laboratories…
- Trial name
- NCT02079909
- Testing
- T-817MA-H, T-817MA-L
- Where
- 50 sites in United States
- Volunteers
- 482 people
- Sponsor
- FUJIFILM Toyama Chemical Co., Ltd.
Alcohol Dependence
A Study for the Treatment of Alcohol Dependence
The Primary objective of this study is to test whether LY2196044 can reduce the number of heavy drinking days per month in people with alcohol dependence.
- Trial name
- NCT00804570
- Testing
- LY2196044
- Where
- 17 sites in United States
- Volunteers
- 375 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia
An extension study of safety and tolerability of SEP-363856 in adult subjects with schizophrenia
- Trial name
- NCT02970929
- Testing
- SEP-363856
- Where
- 30 sites in United States, Hungary and 3 more
- Volunteers
- 157 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Nicotine Addiction, Drug Addiction
Clinical Trial of Smoking Cessation Mobile Phone Program
The Sponsor is doing a research study to assess the effects of a smartphone program designed to help users smoke less and eventually quit. When participants join, their involvement in the core study will last 8 weeks.
- Conditions
- Nicotine Addiction, Drug Addiction, Drug Dependence, Substance Use Disorder
- Trial name
- NCT02656745
- Testing
- Mobile Smoking Cessation Solution
- Where
- United States
- Volunteers
- 416 people
- Sponsor
- Click Therapeutics, Inc.
Schizophrenia Disorders
Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia
This PoC study is designed to assess the cognitive effects of doses of AQW051 in patients with chronic stable schizophrenia.
- Trial name
- NCT01163227
- Testing
- AQW051 2 mg (single and multiple doses), AQW051 15mg (single and multiple doses), AQW051 100mg (single dose), and 50mg (multiple doses)
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.